Browsing by Author Forbes, John

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialCoates, Alan; Campone, N; Castiglione-Gertsch, Monica; Forbes, John; Hawle, H; Mouridsen, Henning; Paridaens, R.J.; Price, K. N.; Rabaglio, Manuela; Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthBone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial, Annals of Oncology, vol.20, 9,pp 1489-1498
2011Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast CancerCoates, Alan; Gebski, Val; Grimison, Peter; Stockler, Martin; Wilcken, Nicholas; Zannino, Diana; Ackland, Stephen; Byrne, Michael J.; Fitzharris, B; Fong, A.; Forbes, John; Francis, Prudence; Gainford, Corona; Harvey, V; Nowak, Anna; Paksec, Lisa; Simes, John; Sourjina, Tatiana; Van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials CentreCapecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer, Journal of Clinical Oncology, vol.29, 34, 2011,pp 4498-4504
2016Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trialLindley, Richard; Berge, Eivind; Cohen, Geoff; et al, Various; Forbes, John; Isaksson, Eva; Lundstrom, Erik; Roaldsen, Melinda B; Rudberg, Ann-Sofie; Slot, Karsten Bruins; Smith, Joel; Western Clinical School: Medicine (Westmead)Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial, The Lancet Neurology, vol.15, 10, 2016,pp 1028-1034
2002First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trialCoates, Alan; Baum, M.; Cawthorn, S.; Cuzick, J.; Edwards, R.; Forbes, John; Hamed, H.; Howell, A.; Powels, T.; School of Public Health: Public HealthFirst results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial, The Lancet, vol.360,(9336),2002,pp 817-824
2017The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysisHackett, Maree; et al, Various; Forbes, John; Gommans, John; Graham, Catriona; Hankey, Graeme; Isaksson, Eva; Lewis, Steff; Lundstrom, Erik; Mead, Gillian; Nguyen, Huy Thang; The George Institute for Global HealthThe FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis, Trials, vol.18, 1, 2017,pp 1-11
2008Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS)Boyle, Frances; Butow, Phyllis; Juraskova, Ilona; Lopez, Anna-Lena; Coates, A; Forbes, John; McCarthy, Nicole; Reaby, L; Seccombe, M; Northern Clinical School: Medicine; Psychology; Psychology; PsychologyImproving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS), Health expectations : an international journal of public participation in health care and health policy, vol.11, 3, 2008,pp 252-262
2008Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerCoates, Alan; Aebi, Stefan; Basser, R; Bernhard, J; et, al; Forbes, John; Hürny, C; Martinelli, G; Yeo, W; Zahrieh, David; Zhang, J J; School of Public Health: Public HealthQuality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer, British Journal of Cancer, vol.98,(1),2008,pp 25-33
2013Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneCoates, Alan; Gebski, Val; Lee, Chee Khoon; Simes, Robert John; Tattersall, Martin; Veillard, Anne-Sophie; Brigham, Brian; Byrne, Michael J.; Forbes, John; Harvey, V; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreTrade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone, SpringerPlus, vol.2, 391, 2013,pp 1-10